Floatz logo

Alisertib

Burkitt Lymphoma

UNC Lineberger Comprehensive Cancer CenterSmall moleculePhase 2Dormant
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

72 Active assets in the Burkitt Lymphoma cohort.

Asset / SponsorPhaseRating
Nivestim
Fred Hutchinson Cancer Center
Phase 4BBB
Vincristine Sulfate
AIDS Malignancy Consortium
Phase 2BBB
Vindesine
PETHEMA Foundation
Phase 4BBB
Cyclosporin A
Fred Hutchinson Cancer Center
Phase 2BBB
Cyclophosphamide
AIDS Malignancy Consortium
Phase 4BBB

View all 50 →

Same molecule, other indications

Alisertib is also rated in:

mantle cell lymphomaActive
BB
Indicative · Phase 2
69 / 100
View asset →
follicular lymphomaDormant
BB
Indicative · Phase 2
69 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
BB
Indicative · Phase 3
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →